Zim Laboratories Ltd
Fri 23/01/2026,15:59:58 | NSE : ZIMLAB
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 71.94
Previous Close
₹ 70.90
Volume
93668
Mkt Cap ( Rs. Cr)
₹342.27
High
₹ 73.36
Low
₹ 68.15
52 Week High
₹ 127.00
52 Week Low
₹ 65.52
Book Value Per Share
₹ 51.57
Dividend Yield
0.00
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Zim Laboratories Ltd
Your Vote -
Buy
50.00%
Hold
0.00%
Sell
50.00%
50.00%
4 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
NaN%
Sell Order Quantity
NaN%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Zim Laboratories Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Zim Laboratories - Notice Of Extra-Ordinary General Meeting Of The Company
-
Zim Laboratories - Shareholders meeting
-
Zim Laboratories - Copy of Newspaper Publication
-
Zim Laboratories - Preferential issue
-
Zim Laboratories - Outcome of Board Meeting
-
Zim Laboratories - Announcement under Regulation 30 (LODR)-Preferential Issue
-
Zim Laboratories - Board Meeting Outcome for Outcome Of Board Meeting Held On 21.01.2026
-
Zim Laboratories - Updates
-
Zim Laboratories - Amended Code Of Practices And Procedures For Fair Disclosure Of Unpublished Prize Sensitive Information
-
Zim Laboratories - Board Meeting Intimation for Considering The Proposal For Raising Funds
-
Zim Laboratories has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2025
-
Zim Laboratories - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Zim Laboratories - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Zim Laboratories - Trading Window
-
Zim Laboratories - Analysts/Institutional Investor Meet/Con. Call Updates
-
Zim Laboratories - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Zim Laboratories - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Zim Laboratories - Analysts/Institutional Investor Meet/Con. Call Updates
-
Zim Laboratories - Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals
-
Zim Laboratories - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Zim Laboratories - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
-
Zim Laboratories - Analysts/Institutional Investor Meet/Con. Call Updates
-
Zim Laboratories - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Zim Laboratories - Analysts/Institutional Investor Meet/Con. Call Updates
-
Zim Laboratories - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report
-
Zim Laboratories - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
-
Zim Laboratories - Shareholders meeting
-
Zim Laboratories - Copy of Newspaper Publication
-
Zim Laboratories Q2 net profit down 90.16% at Rs 0.12 cr
-
Zim Laboratories - Investor Presentation
-
Zim Laboratories - Announcement under Regulation 30 (LODR)-Investor Presentation
-
Zim Laboratories - Results- Quarter And Half Year Ended 30Th September, 2025
-
Zim Laboratories - Outcome of Board Meeting
-
Zim Laboratories - Board Meeting Outcome for Outcome Of Board Meeting Held On 12Th November, 2025
-
Zim Laboratories - Outcome of Board Meeting
-
Zim Laboratories - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Zim Laboratories - Analysts/Institutional Investor Meet/Con. Call Updates
-
Zim Laboratories - Board Meeting Intimation for Considertaion And Approval Of Unaudited Financial Results (Standalone And Con
Key fundamentals
Evaluate the intrinsic value of Zim Laboratories Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 356.6793 | 338.3068 | 253.7463 | 221.2899 | 223.4768 |
| Liabilities | 356.6793 | 338.3068 | 253.7463 | 221.2899 | 223.4768 |
| Equity | 48.7258 | 48.7258 | 48.7258 | 16.2419 | 16.2419 |
| Gross Profit | 43.2684 | 40.1024 | 51.1911 | 37.934 | 36.8113 |
| Net Profit | 11.744 | 16.7555 | 25.0088 | 13.0128 | 5.6162 |
| Cash From Operating Activities | 50.602 | 11.472 | 35.2318 | 47.0265 | 31.8967 |
| NPM(%) | 3.12 | 4.58 | 6.3 | 3.94 | 1.84 |
| Revenue | 375.6355 | 365.4732 | 396.5313 | 329.4937 | 303.6294 |
| Expenses | 332.3671 | 325.3708 | 345.3402 | 291.5597 | 266.8181 |
| ROE(%) | 4.67 | 6.66 | 9.95 | 5.17 | 2.23 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Zim Laboratories Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 689.85 | 0.50 | 0.00 | 40.65 | 301.39 | 0.72 |
| Lotus Eye Hospital and Institute Ltd | 122.17 | 4.98 | 381.78 | 148.13 | 3.55 | 0.00 |
| Vaishali Pharma Ltd | 8.34 | -2.80 | 0.00 | 929.28 | 3.13 | 0.00 |
| Astec Lifesciences Ltd | 569.45 | -4.10 | 0.00 | 139.69 | -604.77 | 0.00 |
Company Info
The company was incorporates in the state of Maharashtra on 14th February, 1984, under the name and style of Zim Laboratories Ltd. The promoters of the company were Shri Z S Vali, Shri M M Kamal, and Shri I A Trivedi. The company is engaged in manufacturing pharmaceutical product in the form of tablets, capsules and syrups. The company became a Public Ltd. Company by passing special resolution dated 25th January 1992 and fresh certificate of incorporation was obtained from Registrar of Companies, Maharashtra Bombay, on 21st January, 1993. The company commenced commercial production on 7th December 1989 and there was no delay in implementation of the project. 2018 -The Company has issued Bonus Shares in the Ratio of 1:1. 2022 -The Company has issued Bonus Shares in the Ratio of 2:1. -Company received Global Nagpur Awards - December 2022. 2023 -Company Received Excellence In Pharma Global Business - April 2023.
The company was incorporates in the state of Maharashtra on 14th February, 1984, under the name and style of Zim Laboratories Ltd. The promoters of the company were Shri Z S Vali, Shri M M Kamal, and Shri I A Trivedi. The company is engaged in manufacturing pharmaceutical product in the form of tablets, capsules and syrups. The company became a Public Ltd. Company by passing special resolution dated 25th January 1992 and fresh certificate of incorporation was obtained from Registrar of Companies, Maharashtra Bombay, on 21st January, 1993. The company commenced commercial production on 7th December 1989 and there was no delay in implementation of the project. 2018 -The Company has issued Bonus Shares in the Ratio of 1:1. 2022 -The Company has issued Bonus Shares in the Ratio of 2:1. -Company received Global Nagpur Awards - December 2022. 2023 -Company Received Excellence In Pharma Global Business - April 2023.
Read More
Parent Organisation
Zim Laboratories Ltd.
Founded
14/02/1984
Managing Director
Dr.Anwar Daud
NSE Symbol
ZIMLABEQ
FAQ
The current price of Zim Laboratories Ltd is ₹ 70.23.
The 52-week high for Zim Laboratories Ltd is ₹ 73.36 and the 52-week low is ₹ 68.15.
The market capitalization of Zim Laboratories Ltd is currently ₹ 342.27. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Zim Laboratories Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Zim Laboratories Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Zim Laboratories Ltd shares.
The CEO of Zim Laboratories Ltd is Dr.Anwar Daud, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.